Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
作者:Michael E. Stokes、Matthew D. Surman、Veronica Calvo、David Surguladze、An-Hu Li、Jennifer Gasparek、Matthew Betzenhauser、Guangyu Zhu、Hongwen Du、Alan C. Rigby、Mark J. Mulvihill
DOI:10.3390/pharmaceutics14102233
日期:——
alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway
蛋白激酶 R (PKR) 样内质网激酶 (PERK) 是负责调节蛋白质合成和缓解 ER 应激的未折叠蛋白反应 (UPR) 的三种内质网 (ER) 跨膜传感器之一。PERK 与肿瘤发生、癌细胞存活以及糖尿病等代谢疾病有关。本文所述的新型扁桃酰胺衍生的吡咯并嘧啶系列 PERK 抑制剂的基于结构的设计和优化导致化合物26的鉴定,该化合物是一种有效的、选择性的和口服生物可利用的化合物,适用于体外和体内研究 PERK 通路生物学, 具有适用于小鼠每天一次口服给药的药代动力学。